Bespak, a specialist inhalation contract development and manufacturing organization (CDMO), has completed its first life cycle assessment (LCA) for its BK357 pressurized Metered Dose Inhaler (pMDI) valve.

The completion of Bespak’s first LCA marks a significant milestone that has been achieved as part of Bespak’s overarching sustainability strategy. It follows Bespak’s investment in manufacturing capabilities at clinical and commercial scale for low carbon pMDIs incorporating the low GWP propellants, HFA-152a & HFO-1234ze.

The project was undertaken to better understand the carbon impact of Bespak’s materials and manufacturing processes, and to increase transparency in the supply chain for pMDIs. The LCA has been independently verified by expert sustainability scientists from Tunley Environmental in line with ISO 14067:2018 standards.

Chris Hirst, CEO of Bespak, said: “The completion of the LCA for our widely used and trusted BK357 pMDI valve demonstrates Bespak’s active commitment to championing sustainability in the supply chain for the benefit of customers, patients and the planet. We are excited to be actively researching solutions for carbon reduction beyond the propellant switch, and are proud to provide credible, independently verified data to back up our environmental claims.”

Benedicta Bakpa, Head of ESG at Bespak, commented: “This important milestone signifies our ongoing commitment to transparency and accountability in driving sustainable operations. As part of our overarching sustainability initiatives, we continue to identify opportunities to reduce our carbon footprint and work towards our near- and long-term net zero targets.”